The group of companies “R-Pharm” has received permission to conduct clinical studies of the drug radotin, the purpose of which will be to study its effectiveness in the treatment of patients with coronavirus infection. The project is implemented in partnership with Korean pharmaceutical company Il-Yang Pharmaceuticals.
2015, the company Il-Yang Pharmaceuticals has filed a patent application on radotin as a means to treat infections, agents which are coronaviruses SARS-CoV and MERS-CoV. In the beginning of 2020 on the site of the Center for biological defense Medical College of Korea University conducted a series of in vitro pharmacological studies, which showed that radotin significantly inhibits the replication of the virus SARS-CoV-2 48 hours after start of treatment.
“R-Pharm” will conduct a multicenter randomized study to assess the efficacy and safety of radotina in the treatment of hospitalized patients with COVID-19 in 11 hospitals in Russia.
Radotin is a low molecular tyrosine kinase inhibitor of Bcr-Abl the second generation which developed by Il-Yang Pharmaceuticals and registered with the Ministry of safety of foodstuff and medicines of the Republic of Korea in 2012 for long-term therapy of patients with chronic myeloid leukemia after failure of therapy with other tyrosine kinase inhibitors. From October 2015, the drug is registered for use in first-line treatment of patients with chronic myeloid leukemia. The safety of radotina studied in several clinical trials.